Darzalex

CAS 945721-28-8

On November 16, 2015, the us FDA approved the release of Daratumumab,

a new monoclonal antibody drug made by Janssen and marketed under the

trade name Darzalex. Clinical use of multiple myeloma after treatment with

protease inhibitors and immunosuppressive agents. The bioengineered drug

is an anti-cd38 monoclonal antibody that targets a transmembrane extracellular

enzyme CD38 molecule highly expressed on the surface of multiple myeloma

cells and can induce rapid death of tumor cells through a variety of mechanisms.

Because healthy cells and all myeloma cells express CD38, adequate evaluation

of drug toxicity and therapeutic efficacy is required.

We can customize according to customer’s requirement

if you have any question pls mail us or call us